Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Tissue-engineered hypertrophic chondrocyte grafts enhanced long bone repair.

Bernhard J., Ferguson J., Rieder B., Heimel P., Nau T., Tangl S.

Animal Study on Cartilage Damage, published in Biomaterials (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biomaterials (2017)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
28622604
DOI
10.1016/j.biomaterials.2017.05.045
Citations
65

Abstract (original English)

Bone has innate ability to regenerate following injury. However, large and complex fractures exceed bone's natural repair capacity and result in non-unions, requiring external intervention to facilitate regeneration. One potential treatment solution, tissue-engineered bone grafts, has been dominated by recapitulating intramembranous ossification (bone formation by osteoblasts), although most serious bone injuries heal by endochondral ossification (bone formation by remodeling of hypertrophic cartilaginous anlage). The field has demonstrated that using endochondral ossification-based strategies can lead to bone deposition. However, stem cell differentiated hypertrophic chondrocytes, the key cell type in endochondral ossification, have not been studied for long bone defect repair. With translation in mind, we created tissue-engineered grafts using human adipose stem cells (ASC), a clinically relevant stem cell source, differentiated into hypertrophic chondrocytes in decellularized bone scaffolds, and implanted these grafts into critical-size femoral defects in athymic rats. Over 12 weeks of implantation, these grafts were compared to acellular scaffolds and grafts engineered using ASC-derived osteoblasts. Grafts engineered using hypertrophic chnodrocytes recapitulated endochondral ossification, as evidenced by the expression of genes and proteins associated with bone formation. M

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnalysis of VarianceAnimalsBone RegenerationCell DifferentiationChondrocytesChondrogenesisDisease Models, AnimalFemoral FracturesFemur

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research